Adempas
(Riociguat)ApprovedSmall molecule
BayerRiociguat is used to treat pulmonary hypertension, a condition where high blood pressure in the lungs makes it harder for the heart to pump blood. It helps relax blood vessels in the lungs to improve blood flow and reduce symptoms like shortness of breath and fatigue.[2] Adempas is currently approved and in use across 12 indications[4].[1]
Adempas is one of 247 small molecule programs targeting Pulmonary Hypertension. It is currently in Approved.
12
Indications
54
Total Trials
4
Active Trials
246
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
157 competitors in Hypertension
#DrugCompanyPhaseTrials
1Adempas
BayerApproved
Baxfendy
AstraZenecaPhase 3
Nitrostat
VViatris Specialty LLC
Phase 3
Minocycline /d
UUniversity of Florida
Phase 3
HCP1803-3
Hanmi Pharmaceutical Company LimitedPhase 3
SGLT2
PProf. Dr. med. Ingo Eitel
Phase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Arterial Hypertension7 trials
Show 4 more trials
A Multicentre Randomised Cross-over Trial of Disease Specific Therapy in Patients With Pulmonary Arterial Hypertension (PAH) Implanted With Pulmonary Artery Pressure and Cardiac Rhythm Monitoring Devices (CardioMEMS/ConfirmRx)
Active, not recruiting·SSheffield Teaching Hospitals NHS Foundation Trust·Approved·NCT05825417·70 enrolled
Pulmonary Hypertension6 trials
Chronic Thromboembolic Pulmonary Hypertension5 trials
CTEPH3 trials
Function2 trials
27 more indications
Hypertension, Pulmonary2 trials
Hemodynamic1 trial
Efficacy and Safety1 trial
Cystic Fibrosis1 trial
Vascular Disease1 trial
Postmenopausal Women1 trial
Treatment1 trial
Left ventricular diastolic dysfunction1 trial
Renal Impairment1 trial
TED1 trial
Blood Pressure1 trial
Chronic Obstructive Pulmonary Disease1 trial
Trial1 trial
THERAPY-HYBRID-BPA Trial
Unknown status·NNational Hospital Organization Okayama Medical Center·Phase 2·NCT04600492·72 enrolled
Itching1 trial
Switching of Sildenafil to Riociguat in CTEPH Patients
Recruiting·—·Phase 4·NCT06715280·30 enrolled
Interstitial Lung Disease1 trial
Headache1 trial
Scleroderma1 trial
Riociguat in Scleroderma Associated Digital Ulcers
Completed·—·Phase 2·NCT02915835·17 enrolled
Efficacy1 trial
Stroke1 trial
Regulatory
FDA Approval Timeline[5]
Oct 8, 2013
ADEMPAS
NDA NDA204819
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Adempas drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Riociguat. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]